121 results about "Intra ocular pressure" patented technology

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include at least two implants preloaded within a delivery device and configured to be implanted within the eye, a metering device configured to transfer energy to the implants for delivery at selected locations within the eye, wherein the metering device is configured to meter a variable amount of energy for each implant delivery event in the eye. The system can further include an injector mechanism configured to serially engage and drive each of the implants.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include a plurality of implants, an external housing, and an introducer assembly. The external housing can provide access to an implant singulation actuator and an implant delivery actuator. The introducer assembly can comprise an auto-retracting introducer portion. The delivery apparatus can include an infinite activation mechanism / portion and / or a manual singulation mechanism / portion.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a grasping body having a longitudinal axis, and a piercing member coupled to the grasping body, including an elongate body and a beveled piercing tip including a long side and a short side, wherein the piercing member includes a proximal segment, a distal segment, and an aperture nested between the proximal segment and the distal segment, wherein the short side and the aperture are coaxially disposed along a central longitudinal axis of the piercing member, and wherein the piercing member is configured to reciprocate along the longitudinal axis relative to the grasping body.

Disclosed herein are systems, devices, kits, and associated methods for treating conditions of the eye by reducing intraocular pressure. The system may include an ocular implant and a delivery device. The ocular implant may be implantable within Schlemm's canal to restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The delivery device may include a cannula comprising a straight proximal portion and a curved distal portion, where the curved distal portion comprises a first curve in a first direction. The delivery device may also include a positioning tool positioned at least partially within the cannula and configured to advance the ocular implant through the cannula, where the positioning tool comprises a curved distal portion biased to form a second curve in a second, different direction.

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

The present disclosure relates to the treatment and / or prevention of glaucoma and other diseases affecting the optic nerve and retinal ganglion cells. In particular, the present disclosure provides novel therapeutic antibodies, and related compositions and methods, that target angiopoietin-related protein 7 (ANGPTL7) to reduce intraocular pressure (IOP) in order to prevent optic nerve damage and restore vision.

A glaucoma treatment apparatus including an imaging device capable of imaging the anterior segment of the eye, a treatment laser, an algorithm programmed to determine a location and a cross sectional area of a treatment based on a customized anatomy of the anterior segment of the eye including the trabecular meshwork (TM), the Schlemm's Canal (SC) and collector channels (CCS), obtained from pre-operative images of the anterior segment of the eye, a pre-operative intraocular pressure (IOP) level and a target IOP reduction as an inputs, and a processor configured to actuate the apparatus to create an outflow channel with a cross-sectional area and location or multiple outflow channels with multiple cross-sectional areas and locations from the anterior chamber (AC) to the SC across the TM, as determined by the algorithm to achieve the target intraocular pressure (IOP) reduction. Also disclosed is a method of reducing intraocular pressure in an eye.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a body for grasping, a piercing member including a proximal segment and a distal segment, the distal segment including a piercing tip at a distal end thereof, and a distal stabilizer element extending from a distal end of the body, the distal stabilizer element including a lumen, wherein the piercing member is configured to reciprocate from a stored position, wherein the proximal segment is retracted within the stabilizer lumen and the piercing tip extends outwardly from the stabilizer, and an extended position, wherein the distal segment and at least a portion of the proximal segment extend outwardly from the stabilizer.

An intraocular pressure (IOP) maintenance device for maintaining IOP is disclosed. The IOP maintenance device includes an inlet configured to receive fluids from a first portion of the eye, an outlet configured to drain the fluids into a second portion of the eye, and a pressure regulator disposed between the inlet and the outlet, the pressure regulator comprising a pressure resistance apparatus configured to fluidly couple the inlet and the outlet when a pressure force from the first portion of the eye exceeds a threshold value, wherein fluid coupling of the inlet and the outlet enables drainage of the fluids from the first portion of the eye to the second portion of the eye to maintain the IOP.

The present invention relates to the technical field of pharmaceuticals, and in particular to a class of nitric oxide (NO) donor-containing compounds or pharmaceutically acceptable salts, a preparation method therefor, a pharmaceutical composition, and a use thereof in the treatment or prevention of an ocular hypertension-related ophthalmic disease and an optic nerve injury-related disease.

The invention relates to the technical field of medical apparatus and instruments, in particular to an intraoperative viscoelastic agent suction instrument for intraocular lens implantation, which comprises a replacement host, a liquid supply pump, a suction pump and a controller electrically connected with the liquid supply pump and the suction pump, the replacement main machine is further provided with a liquid inlet and a liquid outlet which are communicated with the liquid supply pump, and a suction port and a liquid discharge port which are communicated with the suction pump. An input connector and an output connector are arranged at one end of the handle, a replacement pipe is arranged at the other end of the handle, a liquid adding hole and a suction hole are formed in the free end of the replacement pipe, the liquid adding hole is communicated with the input connector, and the suction hole is communicated with the output connector. By balancing perfusion and suction amounts, intraoperative intraocular pressure fluctuation is avoided, intraoperative intraocular pressure caused by high intraocular pressure or intraocular pressure caused by excessive suction is avoided, and therefore the risk of optic nerve or retina injury is reduced.

The present invention relates to the application of an EphA2-specific tyrosine kinase inhibitor, ALW-II-41-27, in ophthalmic diseases. The present invention has confirmed that at a specific concentration, ALW-II-41-27 can inhibit the expression of EphA2 in the retina, reduce the damage of acute high intraocular pressure to retinal tissue, and improve the survival rate of retinal ganglion cells, thereby playing a neuroprotective role, and thus being used for the preparation of treatments for preventing and treating acute high intraocular pressure or glaucoma.

The present disclosure pertains to the field of animal disease models, specifically to a method for constructing an animal model of open-angle glaucoma. In this model, the pathogenesis of open-angle glaucoma is mimicked by inducing necroptosis in trabecular meshwork cells through the injection of IFN-γ into the anterior chamber. This process leads to the inhibition of trabecular meshwork activity and functional impairment, resulting in elevated intraocular pressure and subsequent optic nerve changes indicative of glaucoma. The pathophysiological alterations observed in the animal model closely resemble those seen in human open-angle glaucoma, including chamber angle opening, trabecular meshwork dysfunction, increased intraocular pressure, and loss of RGCs.

The present technology provides systems, devices, and methods for forming blebs to treat ocular hypertension or glaucoma. In some embodiments, a minimally invasive bleb formation device comprises an introducer sheath having a lumen extending longitudinally therethrough. The lumen has a distal end aperture insertable adjacent to a target tissue. The device further includes a wire positionable within the lumen of the introducer sheath. The wire has a first end portion, a second end portion, and an intermediate region between the first end portion and the second end portion. At least a segment of the intermediate portion is configured to extend through the distal end aperture to form a wire loop. The wire loop is moveable between a plurality of positions and is configured to disrupt and cauterize the target tissue.

The purpose of the present invention is to discover an eye drop capable of effectively lowering intraocular pressure even at night, especially during night sleep, in patients with glaucoma or ocular hypertension.　The present invention is an eye drop for lowering intraocular pressure during night sleep in patients suffering from glaucoma or ocular hypertension, the eye drop containing sepetaprost at a concentration of 0.002% (w / v) as an active ingredient.

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral. amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

According to the pharmaceutical composition for treating glaucoma and intraocular hypertension provided by the invention, the stability of the pharmaceutical composition is obviously improved through a salt changing technology; the pharmaceutical composition is prepared from netasdil free alkali or a pharmaceutically acceptable salt thereof, timolol free alkali or a pharmaceutically acceptable salt thereof, and dorzolamide free alkali or a pharmaceutically acceptable salt thereof. The pharmaceutical composition has excellent stability when the pH value is 4.5-5.4. According to the present invention, the effective dose of the pharmaceutical composition is applied to the eyes of the patient requiring the intraocular pressure at the sleeping time or at the time close to the sleeping time once a day, such that the intraocular pressure can be efficiently and rapidly reduced so as to maintain the intraocular pressure in the physiological range for a long time, the side effect is small, and the patient compliance is high.

An ocular compression device with light directed through the sclera. The compression device may detachably house a lighting device that can be used to illuminate the eye area during ophthalmic surgery. Integrating the lighting device with the compression device during the procedure may reduce the number of hands required to perform the surgery. This may be particularly beneficial for ophthalmic surgery where the available surgical space is limited.

The invention discloses a dual-channel drug delivery treatment system for open-angle glaucoma night intraocular hypertension, and relates to the technical field of medical instruments and clinical assistance. The system comprises a central control module, a time window control module, an intelligent double-medicine-bin medicine feeding module, a user interaction module, a data management and analysis module, a communication module, a safety and self-checking module and a power supply and management module. According to the invention, through the time window control module, the traditional morning administration is changed into night administration or individualized administration before intraocular pressure peak, the synchronization of the drug action peak and the night intraocular pressure peak is ensured, and through the intelligent double-drug-bin administration module and the precise metering pump, two drugs with the lowest effective dose are precisely delivered strictly according to the specific sequence of PGA first and CAI second; the time sequence control and precise quantitative administration based on the drug synergistic effect mechanism can ensure the synergistic antihypertensive curative effect, and can obviously avoid the high incidence rate adverse reaction caused by standard dosage combination.

Provided herein are compounds comprising a formula of 4-(3- amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-y I) benzyl adamantane carboxylate (e.g., compounds of formula (I) ) or a pharmaceutically acceptable salt thereof. The compounds are useful for reducing intraocular pressure and for treating glaucoma or ocular hypertension. Formula (I).

The present application relates to a nitric oxide donor-type compound and use thereof in the preparation of a medicament for preventing and / or treating ophthalmic diseases such as glaucoma and ocular hypertension. The compound has a structure represented by formula (I), or is a stereoisomer, tautomer, solvate, metabolite, pharmaceutically acceptable salt, or prodrug of the structure represented by formula (I).

A method and device for reducing intraocular pressure in a patient. The method may comprise administering a viscoelastic material in Schlemm's canal to open aqueous humor outflow pathways. The device is adapted to perform the method. The viscoelastic material may be configured to lower the intraocular pressure within the eye.

Disclosed in the present invention are an intraocular pressure sensing assembly and an intraocular pressure sensing method. The intraocular pressure sensing assembly comprises a lens body, an annular strain gauge, a plurality of regional strain gauges, and a sensing processing circuit, wherein the lens body has a central region and a peripheral region surrounding the central region; the annular strain gauge is arranged in the peripheral region and surrounds the central region; and the plurality of regional strain gauges are arranged at a plurality of predetermined positions in the peripheral region. In response to the intraocular pressure sensing assembly being worn on an eyeball of a subject, the sensing processing circuit measures the eyeball of the subject by means of the annular strain gauge to obtain first stress data, and measures the eyeball of the subject by means of the plurality of regional strain gauges to obtain a plurality of pieces of second stress data corresponding to the plurality of predetermined positions, and the sensing processing circuit further generates intraocular pressure distribution information on the basis of the first stress data and the plurality of pieces of second stress data.

The utility model discloses an intraocular lens positioning hook with injection and suction functions. The intraocular lens positioning hook comprises a positioning hook head; the infusion tube is connected to one side of the positioning hook head; the liquid supply assembly is connected with the infusion tube, and the liquid supply assembly is used for providing intraocular infusion liquid for the infusion tube; the suction pipe is connected to the side, away from the positioning hook head, of the infusion pipe. Intraocular perfusate can be added through the perfusion tube, the stable anterior chamber depth can be maintained through the perfusate, no viscoelastic agent needs to be injected, the operation is faster, more convenient and smoother, if the viscoelastic agent is left in the anterior chamber, the residual viscoelastic agent can be extracted through the suction tube during perfusion of the perfusion tube, the position of the intraocular lens is accurately clamped during the operation, and the operation is more convenient and faster. The positioning is faster, the economic burden of a patient is reduced, the risk of postoperative intraocular hypertension is reduced, the operation time is shortened, and the postoperative vision recovery is faster.

This invention belongs to the field of biomedical technology, specifically relating to an engineered exosome and its applications. This invention is the first to discover that PCDH12 is specifically highly expressed in the trabecular meshwork tissue of glaucoma patients. Based on this target, engineered exosomes loaded with PCDH12 antibodies were successfully developed. These engineered exosomes can achieve non-invasive and precise targeted delivery to the trabecular meshwork tissue. In glaucoma model mouse experiments, they not only significantly reduced intraocular pressure but also effectively protected the optic nerve. The non-invasive and precise delivery strategy proposed in this invention combines potent intraocular pressure reduction with direct neuroprotection, providing a candidate solution with direct clinical translational potential for integrated "pressure reduction-neuroprotection" treatment of glaucoma.

The invention relates to a nitric oxide donor type compound and application thereof in preparation of drugs for preventing and / or treating ophthalmic diseases such as glaucoma and intraocular hypertension. The compound has a structure as shown in a formula (I), or a stereoisomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the structure as shown in the formula (I).

The present disclosure relates to an eye disease implant device, and an eye disease implant device according to an embodiment of the present disclosure includes a tube including a hollow portion through which aqueous humor is drained, wherein one or more wings extending in a direction different from a longitudinal direction of the tube are formed on a portion of an outer surface of the tube. Also, the eye disease implant device may further include a body including a receiving space into which an end of the tube is inserted. In this case, the end of the tube may be inserted into the receiving space to be coupled to the body, or detached from the receiving space to be separated from the body.

The present disclosure pertains to the phakic refractive lenses such as toric lenses, an advanced posterior chamber floating phakic refractive lens (PRL) designed for the correction of severe refractive errors, including myopia, hyperopia, and astigmatism. This innovative lens can reduce or minimize complications commonly associated with traditional phakic intraocular lenses, such as intraocular pressure elevation, cataract formation, and iris pigment dispersion. The phakic refractive lenses such as the toric lenses described herein feature a buoyant, flexible structure with a central aperture to facilitate aqueous humor flow, creating a natural centering force that stabilizes the lens within the pupillary space.